Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
Atara Biotherapeutics, Inc. (ATRA) announces participation in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference. Pascal Touchon, President and CEO, to present on March 6, 2024. Webcast details provided for investors and media.
02/28/2024 - 04:30 PM
THOUSAND OAKS, Calif. --(BUSINESS WIRE)--
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PST / 9:10 a.m. EST.
A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com . An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern California . For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228404331/en/
Investor and Media Relations:
jawe@atarabio.com
Source: Atara Biotherapeutics, Inc.
When is Pascal Touchon, President and CEO of Atara Biotherapeutics, participating in a cell therapy panel discussion?
Pascal Touchon will participate in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference on March 6, 2024.
What is the ticker symbol for Atara Biotherapeutics?
The ticker symbol for Atara Biotherapeutics is ATRA.
Where can investors and media access the live webcast of the presentation?
Investors and media can access the live webcast of the presentation by visiting the Investors and Media section of atarabio.com.
How long will the archived replay of the webcast be available on the Company's website?
The archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
Atara Biotherapeutics Inc
ATRA Rankings
#5201 Ranked by Stock Gains
ATRA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
South San Francisco
About ATRA
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
